TITLE

Pergolide and cabergoline were associated with increased risk for newly diagnosed cardiac valve regurgitation

AUTHOR(S)
Schade, R.; Andersohn, F.; Suissa, S.; Haverkamp, W.; Garbe, E.
PUB. DATE
May 2007
SOURCE
ACP Journal Club;May/Jun2007, Vol. 146 Issue 3, p75
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents a study which examines whether dopamine agonists increase the risk of newly diagnosed cardiac valve regurgitation in patients taking anti-Parkinsonian drugs. Results revealed that the use of pergolide and cabergoline has led to higher risk of newly diagnosed cardiac valve than dopamine agonists. It is concluded that dopamine agonists anti-Parkinsonian drugs, pergolide and cabergoline were associated with the increased risk for cardiac valve regurgitation.
ACCESSION #
25169127

 

Related Articles

  • Pergolide and cabergoline were associated with increased risk for newly diagnosed cardiac valve regurgitation: COMMENTARY. Massel, David; Suskin, Neville // ACP Journal Club;May/Jun2007, Vol. 146 Issue 3, p75 

    The author comments on a study which examines whether dopamine agonists increase the risk of newly diagnosed cardiac valve regurgitation in patients taking antiparkinsonian drugs. He asserted that the estimates of drug-induced valvular disease in the study are probably unstable and the...

  • Pergolide and cabergoline increased risk for valvular heart disease in Parkinson disease. Zanettini, R.; Antonini, A.; Gatto, G. // ACP Journal Club;May/Jun2007, Vol. 146 Issue 3, p76 

    The article presents a study which examines whether pergolide, cabergoline and non-ergot-derived dopamine agonists increase the risk of valvular heart disease in patients with Parkinson's disease. Results revealed that pergolide and cabergoline groups has a higher risk of moderate-to-severe...

  • Dopamine agonists and valvular heart disease in patients with Parkinson's disease: evidence and mystery. Yamamoto, Mitsutoshi; Uesugi, Tadahisa // Journal of Neurology;Sep2007, Vol. 254 Issue S5, p74 

    High doses of the ergot dopamine agonists, pergolide and cabergoline, frequently cause valvular regurgitation and, somewhat less frequently, valvular heart disease (VHD) in Parkinson's disease. Most patients with valvular regurgitation have no cardiac signs and symptoms. Reports from Asian...

  • Prescribing Pattern of Anti-Parkinson Drugs in Japan: A Trend Analysis from 2005 to 2010. Nakaoka, Sachiko; Ishizaki, Tatsuro; Urushihara, Hisashi; Satoh, Toshihiko; Ikeda, Shunya; Yamamoto, Mitsutoshi; Nakayama, Takeo // PLoS ONE;Jun2014, Vol. 9 Issue 6, p1 

    Objective: Therapeutic options for Parkinson's disease mainly consist of L-dopa and dopamine agonists. However, in Japan, the product labeling of the ergot dopamine agonists, cabergoline and pergolide, was revised in April 2007 due to the risk of developing cardiac valvulopathy. Here, we...

  • Pergolide.  // Reactions Weekly;1/9/2010 Part 1 of 2, Issue 1283, p75 

    The article describes the case of a 49-year-old woman who developed valvular heart disease while receiving dopamine receptor agonist pergolide for restless legs syndrome (RLS). It was diagnosed during her cardiology consultation that she is suffering from moderate-to-severe mitral regurgitation,...

  • Cabergoline.  // Reactions Weekly;6/20/2009, Issue 1257, p12 

    The article describes the case of an elderly man who developed valvular heart disease while receiving cabergoline for pituitary macroprolactinoma. Upon hospitalization, the patient presented with left ventricular failure. Based on his echocardiography, his left ventricle is mildly dilated and he...

  • Pergolide Off the Market, Heart Disease Risk. Elliott, William T. // Clinical Cardiology Alert;May2007 Pharmacology Watch, p2 

    The article reports on the withdrawal of pergolide from the market after findings of serious valvular heart disease associated with the drug. The drug is a dopamine agonist used in treating Parkinson' disease, hyperprolactinemia and pituitary tumor. The removal of the drug from the market was...

  • Risks of Cardiac Valve Regurgitation and Heart Failure Associated with Ergot- and Non-Ergot-Derived Dopamine Agonist Use in Patients with Parkinson's Disease: A Systematic Review of Observational Studies. Tran, Tanja; Brophy, James; Suissa, Samy; Renoux, Christel; Brophy, James M // CNS Drugs;Dec2015, Vol. 29 Issue 12, p985 

    Background: Dopamine agonists (DAs) are commonly used in the therapy of Parkinson's disease (PD). However, several observational studies have suggested a putative association between DAs and specific cardiac adverse events.Objectives: The aim of this study was to...

  • Parkinson's disease. Walker, Richard // Pulse;10/27/2010, Vol. 70 Issue 32, p25 

    The article discusses how to treat idiopathic Parkinson's disease (IPD). The disease can be treated by dopaminergic medication using drugs that can provide symptomatic control including dopamine agonists, levodopa and amantadine, however, these drugs have side-effects such as nausea, orthostatic...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics